Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New injection shows promise for smoothing frown lines and Crow's feet

NCT ID NCT05148000

Symptom relief Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new injection called QM1114-DP in 25 adults with moderate to severe frown lines and crow's feet. Participants received one treatment and were asked to rate how much their appearance improved. The goal was to see if the treatment could make these wrinkles look better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
QM1114-DP (a botulinum toxin type A injection)
What this could lead to
If successful, this could provide a new option for temporarily reducing the appearance of frown lines and crow's feet.
What could go wrong
This is a small, completed Phase 3 study with only 25 participants. Results may not apply to everyone, and effects are temporary. Allergic reactions or bruising at injection site are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

25 people

The number who actually took part.

Started

Jan 2023

Finished

Jun 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female 18 years or older * Moderate to severe bilaterally symmetrical LCL as assessed by the investigator * Moderate to severe GL at maximum frown as assessed by the Investigator Exclusion Criteria: * Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment * Female who was pregnant, breast feeding or intended to conceive a child during the study. * Known allergy to hypersensitivity or any component of the Investigational product

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Canthal lines are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Canthal lines Glabellar frown lines

Contacts and locations

Locations

  • Galderma Research Site

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.